vs
PAMT CORP（PAMT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是PAMT CORP的1.5倍（$207.3M vs $141.3M），PAMT CORP净利率更高（-20.7% vs -62.0%，领先41.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -15.1%），PAMT CORP自由现金流更多（$-25.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -12.0%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PAMT vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$141.3M
营收增速更快
RARE
高出41.0%
-15.1%
净利率更高
PAMT
高出41.3%
-62.0%
自由现金流更多
PAMT
多$75.8M
$-100.8M
两年增速更快
RARE
近两年复合增速
-12.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.3M | $207.3M |
| 净利润 | $-29.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -27.0% | -54.7% |
| 净利率 | -20.7% | -62.0% |
| 营收同比 | -15.1% | 25.9% |
| 净利润同比 | 7.4% | 3.5% |
| 每股收益（稀释后） | $-1.38 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAMTRARE
| Q4 25 | $141.3M | $207.3M | ||
| Q3 25 | $150.3M | $159.9M | ||
| Q2 25 | $151.1M | $166.5M | ||
| Q1 25 | $155.3M | $139.3M | ||
| Q4 24 | $166.5M | $164.6M | ||
| Q3 24 | $182.6M | $139.5M | ||
| Q2 24 | $182.9M | $147.0M | ||
| Q1 24 | $182.6M | $108.8M |
净利润PAMTRARE
| Q4 25 | $-29.3M | $-128.6M | ||
| Q3 25 | $-5.6M | $-180.4M | ||
| Q2 25 | $-9.6M | $-115.0M | ||
| Q1 25 | $-8.1M | $-151.1M | ||
| Q4 24 | $-31.6M | $-133.2M | ||
| Q3 24 | $2.4M | $-133.5M | ||
| Q2 24 | $-2.9M | $-131.6M | ||
| Q1 24 | $281.0K | $-170.7M |
营业利润率PAMTRARE
| Q4 25 | -27.0% | -54.7% | ||
| Q3 25 | -3.8% | -106.9% | ||
| Q2 25 | -7.3% | -64.8% | ||
| Q1 25 | -5.9% | -102.6% | ||
| Q4 24 | -22.6% | -74.3% | ||
| Q3 24 | 1.3% | -94.6% | ||
| Q2 24 | -0.4% | -79.1% | ||
| Q1 24 | -0.4% | -151.9% |
净利率PAMTRARE
| Q4 25 | -20.7% | -62.0% | ||
| Q3 25 | -3.7% | -112.8% | ||
| Q2 25 | -6.4% | -69.0% | ||
| Q1 25 | -5.2% | -108.5% | ||
| Q4 24 | -19.0% | -80.9% | ||
| Q3 24 | 1.3% | -95.7% | ||
| Q2 24 | -1.6% | -89.5% | ||
| Q1 24 | 0.2% | -156.8% |
每股收益（稀释后）PAMTRARE
| Q4 25 | $-1.38 | $-1.28 | ||
| Q3 25 | $-0.27 | $-1.81 | ||
| Q2 25 | $-0.46 | $-1.17 | ||
| Q1 25 | $-0.37 | $-1.57 | ||
| Q4 24 | $-1.44 | $-1.34 | ||
| Q3 24 | $0.11 | $-1.40 | ||
| Q2 24 | $-0.13 | $-1.52 | ||
| Q1 24 | $0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.7M | $421.0M |
| 总债务越低越好 | $333.9M | — |
| 股东权益账面价值 | $210.5M | $-80.0M |
| 总资产 | $697.9M | $1.5B |
| 负债/权益比越低杠杆越低 | 1.59× | — |
8季度趋势，按日历期对齐
现金及短期投资PAMTRARE
| Q4 25 | $83.7M | $421.0M | ||
| Q3 25 | $115.6M | $202.5M | ||
| Q2 25 | $117.3M | $176.3M | ||
| Q1 25 | $102.7M | $127.1M | ||
| Q4 24 | $110.7M | $174.0M | ||
| Q3 24 | $92.3M | $150.6M | ||
| Q2 24 | $114.0M | $480.7M | ||
| Q1 24 | $125.8M | $112.3M |
总债务PAMTRARE
| Q4 25 | $333.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $325.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PAMTRARE
| Q4 25 | $210.5M | $-80.0M | ||
| Q3 25 | $239.5M | $9.2M | ||
| Q2 25 | $244.9M | $151.3M | ||
| Q1 25 | $269.6M | $144.2M | ||
| Q4 24 | $277.5M | $255.0M | ||
| Q3 24 | $308.9M | $346.8M | ||
| Q2 24 | $306.7M | $432.4M | ||
| Q1 24 | $314.6M | $140.3M |
总资产PAMTRARE
| Q4 25 | $697.9M | $1.5B | ||
| Q3 25 | $715.2M | $1.2B | ||
| Q2 25 | $707.9M | $1.3B | ||
| Q1 25 | $712.6M | $1.3B | ||
| Q4 24 | $741.7M | $1.5B | ||
| Q3 24 | $756.7M | $1.5B | ||
| Q2 24 | $733.5M | $1.6B | ||
| Q1 24 | $746.4M | $1.3B |
负债/权益比PAMTRARE
| Q4 25 | 1.59× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-25.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | -17.7% | -48.6% |
| 资本支出强度资本支出/营收 | 13.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.4M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PAMTRARE
| Q4 25 | $-5.8M | $-99.8M | ||
| Q3 25 | $5.9M | $-91.4M | ||
| Q2 25 | $12.2M | $-108.3M | ||
| Q1 25 | $5.0M | $-166.5M | ||
| Q4 24 | $15.2M | $-79.3M | ||
| Q3 24 | $15.5M | $-67.0M | ||
| Q2 24 | $18.7M | $-77.0M | ||
| Q1 24 | $9.6M | $-190.7M |
自由现金流PAMTRARE
| Q4 25 | $-25.0M | $-100.8M | ||
| Q3 25 | $2.5M | $-92.7M | ||
| Q2 25 | $5.9M | $-110.7M | ||
| Q1 25 | $-6.8M | $-167.8M | ||
| Q4 24 | $-39.9M | $-79.5M | ||
| Q3 24 | $-33.6M | $-68.6M | ||
| Q2 24 | $4.1M | $-79.0M | ||
| Q1 24 | $-12.2M | $-193.9M |
自由现金流率PAMTRARE
| Q4 25 | -17.7% | -48.6% | ||
| Q3 25 | 1.7% | -58.0% | ||
| Q2 25 | 3.9% | -66.5% | ||
| Q1 25 | -4.4% | -120.5% | ||
| Q4 24 | -24.0% | -48.3% | ||
| Q3 24 | -18.4% | -49.2% | ||
| Q2 24 | 2.2% | -53.7% | ||
| Q1 24 | -6.7% | -178.2% |
资本支出强度PAMTRARE
| Q4 25 | 13.6% | 0.5% | ||
| Q3 25 | 2.3% | 0.8% | ||
| Q2 25 | 4.2% | 1.5% | ||
| Q1 25 | 7.6% | 1.0% | ||
| Q4 24 | 33.1% | 0.1% | ||
| Q3 24 | 26.9% | 1.2% | ||
| Q2 24 | 8.0% | 1.4% | ||
| Q1 24 | 12.0% | 3.0% |
现金转化率PAMTRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.44× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 34.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
